Boundless Bio Launches With $46m And Novel Oncology Focus On Extrachromosomal DNA

 
• By Mandy Jackson

Former Ignyta executive Zachary Hornby wasn't wowed by immuno-oncology pitches when looking for his next cancer drug development company, but was intrigued by ecDNA research at UCSD, which also could generate a tumor agnostic approach.

DNA strand and Cancer Cell Oncology Research Concept 3D rendering - Illustration
Boundless Bio is focused on extrachromosomal DNA as a cause of rapid tumor growth. • Source: Shutterstock

More from Start-Ups & SMEs

More from Business